Veterinary Anti-infectives Market by Product Type (Antibiotics, Antifungals, Antiparasitics), Route Of Administration (Injectable, Oral, Topical), Animal Type, Distribution Channel, Application - Global Forecast 2025-2032
Description
The Veterinary Anti-infectives Market was valued at USD 4.28 billion in 2024 and is projected to grow to USD 4.81 billion in 2025, with a CAGR of 12.38%, reaching USD 10.90 billion by 2032.
A strategic primer connecting clinical demand, commercial realities, and regulatory pressures to orient executives within the modern veterinary anti-infectives ecosystem
This introduction frames the current veterinary anti-infectives environment by connecting clinical needs, commercial realities, and regulatory drivers into a coherent narrative that supports strategic decision-making. Over recent years, animal health stakeholders have experienced accelerating complexity across supply chains, an expanding therapeutic toolkit, and heightened attention to antimicrobial stewardship, all of which are reshaping how products are developed, distributed, and prescribed.
Consequently, executives and technical leaders must balance short-term operational resilience with longer-term innovation roadmaps. This summary synthesizes key industry movements, identifies inflection points for manufacturers and distributors, and outlines where risk and opportunity intersect. By clarifying the interplay between product portfolios, administration routes, and end-user segments, this introduction establishes the foundational context for the more detailed insights that follow.
How scientific advances in drug design, diagnostics, and digital distribution are fundamentally reshaping development priorities and commercial strategies in veterinary anti-infectives
The veterinary anti-infectives landscape is undergoing transformative shifts driven by scientific innovation, evolving stewardship frameworks, and changing customer behaviors. Novel formulation approaches and advances in pharmacokinetics are enabling targeted delivery and improved therapeutic windows, while parallel progress in diagnostic capabilities supports more precise treatment selection at the point of care. As a result, product development priorities are moving from broad-spectrum solutions toward differentiated, value-added therapies that demonstrate improved safety, efficacy, and compliance.
At the same time, market dynamics are being reshaped by distribution channel evolution and digital adoption. Veterinary clinics and hospitals are increasingly integrating electronic medical records and telemedicine tools that influence prescribing patterns, while online pharmacies expand access and convenience for companion animal owners. Meanwhile, livestock and aquaculture operations are adopting integrated health-management systems that prioritize preventive interventions and data-driven decision-making. These combined forces are prompting companies to reorient commercial strategies, invest in diagnostic-commercial partnerships, and refine go-to-market models that emphasize outcomes and traceability.
Examining the multifaceted and lasting supply chain consequences of the 2025 U.S. tariff measures and how industry actors adapted procurement, manufacturing, and distribution strategies
The introduction of new tariff measures in the United States in 2025 has reverberated across the veterinary anti-infectives value chain, with cumulative effects that extend beyond immediate cost pressures. Supply chain sensitivity has increased, particularly for active pharmaceutical ingredients and specialty excipients that are sourced globally. As import-related charges and administrative burdens rose, many manufacturers accelerated supplier diversification, nearshoring, and inventory optimization initiatives to maintain continuity of supply and protect margins.
These trade-related dynamics have also incentivized a reevaluation of manufacturing footprints. In response, firms have prioritized strategic investments in domestic production capacity and strengthened relationships with regional contract manufacturers to mitigate exposure to border disruptions. In parallel, procurement teams applied more rigorous total-cost-of-ownership frameworks, accounting for lead-time variability and regulatory compliance expenses in sourcing decisions. Consequently, commercial stakeholders faced a period of adaptation in pricing negotiations, contract terms with distributors, and customer communication strategies to preserve trust while managing incremental cost pass-throughs. Over time, these adaptations contributed to a more resilient, albeit more complex, supply ecosystem that emphasizes agility and contingency planning.
Multidimensional segmentation insights clarifying how product classes, administration routes, animal species, distribution pathways, and use cases jointly determine strategic priorities
Segmentation analysis reveals how product type, route of administration, animal type, distribution channel, and application collectively shape demand patterns and competitive positioning. Products span distinct classes including antibiotics with subclasses such as aminoglycosides, beta lactams, fluoroquinolones, macrolides, sulfonamides, and tetracyclines; antifungals including azoles and polyenes; and antiparasitics covering acaricides, anthelmintics, and insecticides. Each product family carries differentiated development considerations, regulatory pathways, and stewardship expectations, which influence R&D prioritization and labeling strategies. For example, molecular classes with established efficacy profiles tend to face pressure for improved formulations and delivery options to extend therapeutic relevance.
Route of administration creates operational and commercial nuances. Injectable options, including intramuscular, intravenous, and subcutaneous formats, demand specific cold-chain and administration training, whereas oral formats offered as pellets, powders, suspensions, or tablets prioritize palatability and dosing compliance. Topical formulations such as creams, dips, ointments, and sprays emphasize ease of application and owner acceptance. Animal type segmentation further refines targeting: aquaculture solutions for fish and shrimp require compatibility with aquatic systems and environmental considerations; companion animal therapies for cats and dogs focus on safety, taste, and owner convenience; livestock therapies for cattle, goats, sheep, and swine are designed around herd-level administration and withdrawal profiles; and poultry solutions for chicken and turkey must integrate into flock health routines. Distribution channel differences also matter: online pharmacies, retail pharmacies, veterinary clinics, and veterinary hospitals each present unique buying behaviors, regulatory constraints, and service expectations. Finally, application use-prophylactic versus therapeutic-affects product positioning, messaging, and contract structures, as preventive products are often tied to management programs while therapeutics emphasize clinical outcomes and treatment pathways. Taken together, these intersecting segmentation layers require companies to deploy nuanced portfolio strategies that align formulation science, supply-chain capabilities, and commercial approaches with the specific operational realities of each end-user group.
Regional patterns that influence product strategies and commercialization across the Americas, Europe Middle East & Africa, and Asia-Pacific with an emphasis on regulation and infrastructure
Regional dynamics remain a decisive factor for strategic planning, with distinct commercial motifs emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, institutional purchasing structures and a mature companion animal market drive demand for branded, convenience-focused formulations and integrated clinic services. Regulatory frameworks and stewardship programs in this region emphasize responsible use and surveillance, influencing promotional activities and label claims.
Across Europe, the Middle East & Africa, diverse regulatory regimes and varying levels of veterinary infrastructure necessitate adaptable market-entry models. In many European markets, strong public awareness of antimicrobial resistance and tight regulation of certain antibiotic classes push companies toward differentiated, evidence-backed products and enhanced post-market monitoring. Meanwhile, in parts of the Middle East & Africa, opportunities often hinge on improving access, cold-chain robustness, and targeted educational initiatives. The Asia-Pacific region presents a multifaceted landscape where rapid intensification in livestock and aquaculture production coincides with expanding companion animal ownership. Policymakers and industry participants in these markets increasingly prioritize biosecurity and supply-chain transparency, prompting investments in diagnostics, stewardship training, and regional manufacturing partnerships to meet local demand profiles and regulatory expectations.
How leading firms are aligning R&D, manufacturing partnerships, and channel strategies to build differentiated product-service propositions in veterinary anti-infectives
Company behavior in the veterinary anti-infectives sector has clustered around several clear strategic themes that shape competitive dynamics. Leading manufacturers and innovators are investing in differentiation through formulation science, seeking proprietary delivery systems and extended-release technologies that improve dosing convenience and adherence. Simultaneously, many organizations pursue strategic alliances with diagnostic developers to create bundled solutions that support targeted therapy and stewardship goals. In parallel, contract development and manufacturing organizations have expanded capacity and capabilities to serve both legacy generics and higher-margin specialty products, reflecting a broader industry pivot toward flexible manufacturing models.
Commercially, companies are refining channel strategies to balance direct clinic engagement with broader retail and online distribution. Those that excel tend to pair traditional salesforce efforts with digital tools that enhance product education, compliance tracking, and telemetry. Additionally, corporate development activity-ranging from selective acquisitions to licensing agreements-has prioritized assets that complement product pipelines or extend geographic reach while reducing time-to-market complexity. Taken together, these strategic moves illustrate how firms are building integrated value propositions that fuse product performance with service-oriented solutions and supply reliability.
Concrete, high-impact recommendations for manufacturers and distributors to improve resilience, accelerate targeted therapies, and align commercial models with stewardship expectations
Industry leaders should prioritize a set of actionable responses to navigate current market complexities and capture strategic upside. First, strengthen supply-chain resilience by diversifying API sources, qualifying regional contract manufacturers, and implementing scenario-based inventory planning. These measures reduce vulnerability to trade disruptions and support reliable product availability. Second, accelerate partnerships between therapeutic developers and diagnostic providers to enable targeted treatment approaches that align with antimicrobial stewardship principles; such collaborations will enhance clinical credibility and create new commercial pathways.
Third, invest in formulation and delivery innovations that address route-specific challenges and end-user preferences, such as palatability for oral products and user-friendly topical formats. Fourth, tailor commercial models to the realities of different distribution channels and animal types by aligning sample programs, training content, and digital tools with clinic workflows and retail expectations. Finally, embed regulatory and stewardship considerations into early-stage development to smooth approvals and support clear, defensible labeling. Collectively, these actions will help organizations improve market access, increase therapeutic impact, and sustain long-term brand value.
A transparent, practitioner-oriented research approach combining expert interviews, technical dossier reviews, and supply-chain analysis to generate validated strategic insights
The research methodology underpinning this executive summary synthesizes primary and secondary intelligence to produce balanced, actionable insights. Primary inputs included structured interviews and targeted consultations with veterinary clinicians, regulatory experts, procurement officers, and commercial leaders to capture real-world operational perspectives and decision criteria. These engagements were complemented by product- and formulation-level technical reviews to assess development challenges and approval pathways.
Secondary inputs comprised a curated review of regulatory guidance, scientific literature, and trade publications to validate trends and contextualize policy shifts. Where relevant, supply-chain analyses were conducted to trace sourcing dependencies and logistic constraints. Throughout the process, cross-validation techniques were used to reconcile divergent viewpoints and ensure the robustness of qualitative conclusions. This combined approach emphasizes methodological transparency, triangulation of evidence, and practitioner-oriented synthesis to support credible recommendations.
A concise synthesis of strategic imperatives showing how innovation, stewardship, and supply resilience collectively shape future success in veterinary anti-infectives
In conclusion, the veterinary anti-infectives arena is at an inflection point where scientific innovation, regulatory scrutiny, and distribution transformation intersect to create both challenge and opportunity. Companies that realign R&D toward differentiated formulations, embed stewardship through diagnostic partnerships, and fortify supply chains will be best positioned to serve diverse animal health markets. Moreover, adapting commercial models to the specific demands of clinics, hospitals, retail, and online channels will accelerate adoption and improve therapeutic outcomes.
As stakeholders pursue these objectives, disciplined execution and continuous stakeholder engagement will be essential. Decision-makers should prioritize pragmatic investments that deliver measurable improvements in availability, efficacy, and compliance, while remaining vigilant to policy changes and trade dynamics that can shift operating assumptions. With a focused strategy, the industry can simultaneously advance animal health, support responsible antimicrobial use, and create sustainable commercial value.
Please Note: PDF & Excel + Online Access - 1 Year
A strategic primer connecting clinical demand, commercial realities, and regulatory pressures to orient executives within the modern veterinary anti-infectives ecosystem
This introduction frames the current veterinary anti-infectives environment by connecting clinical needs, commercial realities, and regulatory drivers into a coherent narrative that supports strategic decision-making. Over recent years, animal health stakeholders have experienced accelerating complexity across supply chains, an expanding therapeutic toolkit, and heightened attention to antimicrobial stewardship, all of which are reshaping how products are developed, distributed, and prescribed.
Consequently, executives and technical leaders must balance short-term operational resilience with longer-term innovation roadmaps. This summary synthesizes key industry movements, identifies inflection points for manufacturers and distributors, and outlines where risk and opportunity intersect. By clarifying the interplay between product portfolios, administration routes, and end-user segments, this introduction establishes the foundational context for the more detailed insights that follow.
How scientific advances in drug design, diagnostics, and digital distribution are fundamentally reshaping development priorities and commercial strategies in veterinary anti-infectives
The veterinary anti-infectives landscape is undergoing transformative shifts driven by scientific innovation, evolving stewardship frameworks, and changing customer behaviors. Novel formulation approaches and advances in pharmacokinetics are enabling targeted delivery and improved therapeutic windows, while parallel progress in diagnostic capabilities supports more precise treatment selection at the point of care. As a result, product development priorities are moving from broad-spectrum solutions toward differentiated, value-added therapies that demonstrate improved safety, efficacy, and compliance.
At the same time, market dynamics are being reshaped by distribution channel evolution and digital adoption. Veterinary clinics and hospitals are increasingly integrating electronic medical records and telemedicine tools that influence prescribing patterns, while online pharmacies expand access and convenience for companion animal owners. Meanwhile, livestock and aquaculture operations are adopting integrated health-management systems that prioritize preventive interventions and data-driven decision-making. These combined forces are prompting companies to reorient commercial strategies, invest in diagnostic-commercial partnerships, and refine go-to-market models that emphasize outcomes and traceability.
Examining the multifaceted and lasting supply chain consequences of the 2025 U.S. tariff measures and how industry actors adapted procurement, manufacturing, and distribution strategies
The introduction of new tariff measures in the United States in 2025 has reverberated across the veterinary anti-infectives value chain, with cumulative effects that extend beyond immediate cost pressures. Supply chain sensitivity has increased, particularly for active pharmaceutical ingredients and specialty excipients that are sourced globally. As import-related charges and administrative burdens rose, many manufacturers accelerated supplier diversification, nearshoring, and inventory optimization initiatives to maintain continuity of supply and protect margins.
These trade-related dynamics have also incentivized a reevaluation of manufacturing footprints. In response, firms have prioritized strategic investments in domestic production capacity and strengthened relationships with regional contract manufacturers to mitigate exposure to border disruptions. In parallel, procurement teams applied more rigorous total-cost-of-ownership frameworks, accounting for lead-time variability and regulatory compliance expenses in sourcing decisions. Consequently, commercial stakeholders faced a period of adaptation in pricing negotiations, contract terms with distributors, and customer communication strategies to preserve trust while managing incremental cost pass-throughs. Over time, these adaptations contributed to a more resilient, albeit more complex, supply ecosystem that emphasizes agility and contingency planning.
Multidimensional segmentation insights clarifying how product classes, administration routes, animal species, distribution pathways, and use cases jointly determine strategic priorities
Segmentation analysis reveals how product type, route of administration, animal type, distribution channel, and application collectively shape demand patterns and competitive positioning. Products span distinct classes including antibiotics with subclasses such as aminoglycosides, beta lactams, fluoroquinolones, macrolides, sulfonamides, and tetracyclines; antifungals including azoles and polyenes; and antiparasitics covering acaricides, anthelmintics, and insecticides. Each product family carries differentiated development considerations, regulatory pathways, and stewardship expectations, which influence R&D prioritization and labeling strategies. For example, molecular classes with established efficacy profiles tend to face pressure for improved formulations and delivery options to extend therapeutic relevance.
Route of administration creates operational and commercial nuances. Injectable options, including intramuscular, intravenous, and subcutaneous formats, demand specific cold-chain and administration training, whereas oral formats offered as pellets, powders, suspensions, or tablets prioritize palatability and dosing compliance. Topical formulations such as creams, dips, ointments, and sprays emphasize ease of application and owner acceptance. Animal type segmentation further refines targeting: aquaculture solutions for fish and shrimp require compatibility with aquatic systems and environmental considerations; companion animal therapies for cats and dogs focus on safety, taste, and owner convenience; livestock therapies for cattle, goats, sheep, and swine are designed around herd-level administration and withdrawal profiles; and poultry solutions for chicken and turkey must integrate into flock health routines. Distribution channel differences also matter: online pharmacies, retail pharmacies, veterinary clinics, and veterinary hospitals each present unique buying behaviors, regulatory constraints, and service expectations. Finally, application use-prophylactic versus therapeutic-affects product positioning, messaging, and contract structures, as preventive products are often tied to management programs while therapeutics emphasize clinical outcomes and treatment pathways. Taken together, these intersecting segmentation layers require companies to deploy nuanced portfolio strategies that align formulation science, supply-chain capabilities, and commercial approaches with the specific operational realities of each end-user group.
Regional patterns that influence product strategies and commercialization across the Americas, Europe Middle East & Africa, and Asia-Pacific with an emphasis on regulation and infrastructure
Regional dynamics remain a decisive factor for strategic planning, with distinct commercial motifs emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, institutional purchasing structures and a mature companion animal market drive demand for branded, convenience-focused formulations and integrated clinic services. Regulatory frameworks and stewardship programs in this region emphasize responsible use and surveillance, influencing promotional activities and label claims.
Across Europe, the Middle East & Africa, diverse regulatory regimes and varying levels of veterinary infrastructure necessitate adaptable market-entry models. In many European markets, strong public awareness of antimicrobial resistance and tight regulation of certain antibiotic classes push companies toward differentiated, evidence-backed products and enhanced post-market monitoring. Meanwhile, in parts of the Middle East & Africa, opportunities often hinge on improving access, cold-chain robustness, and targeted educational initiatives. The Asia-Pacific region presents a multifaceted landscape where rapid intensification in livestock and aquaculture production coincides with expanding companion animal ownership. Policymakers and industry participants in these markets increasingly prioritize biosecurity and supply-chain transparency, prompting investments in diagnostics, stewardship training, and regional manufacturing partnerships to meet local demand profiles and regulatory expectations.
How leading firms are aligning R&D, manufacturing partnerships, and channel strategies to build differentiated product-service propositions in veterinary anti-infectives
Company behavior in the veterinary anti-infectives sector has clustered around several clear strategic themes that shape competitive dynamics. Leading manufacturers and innovators are investing in differentiation through formulation science, seeking proprietary delivery systems and extended-release technologies that improve dosing convenience and adherence. Simultaneously, many organizations pursue strategic alliances with diagnostic developers to create bundled solutions that support targeted therapy and stewardship goals. In parallel, contract development and manufacturing organizations have expanded capacity and capabilities to serve both legacy generics and higher-margin specialty products, reflecting a broader industry pivot toward flexible manufacturing models.
Commercially, companies are refining channel strategies to balance direct clinic engagement with broader retail and online distribution. Those that excel tend to pair traditional salesforce efforts with digital tools that enhance product education, compliance tracking, and telemetry. Additionally, corporate development activity-ranging from selective acquisitions to licensing agreements-has prioritized assets that complement product pipelines or extend geographic reach while reducing time-to-market complexity. Taken together, these strategic moves illustrate how firms are building integrated value propositions that fuse product performance with service-oriented solutions and supply reliability.
Concrete, high-impact recommendations for manufacturers and distributors to improve resilience, accelerate targeted therapies, and align commercial models with stewardship expectations
Industry leaders should prioritize a set of actionable responses to navigate current market complexities and capture strategic upside. First, strengthen supply-chain resilience by diversifying API sources, qualifying regional contract manufacturers, and implementing scenario-based inventory planning. These measures reduce vulnerability to trade disruptions and support reliable product availability. Second, accelerate partnerships between therapeutic developers and diagnostic providers to enable targeted treatment approaches that align with antimicrobial stewardship principles; such collaborations will enhance clinical credibility and create new commercial pathways.
Third, invest in formulation and delivery innovations that address route-specific challenges and end-user preferences, such as palatability for oral products and user-friendly topical formats. Fourth, tailor commercial models to the realities of different distribution channels and animal types by aligning sample programs, training content, and digital tools with clinic workflows and retail expectations. Finally, embed regulatory and stewardship considerations into early-stage development to smooth approvals and support clear, defensible labeling. Collectively, these actions will help organizations improve market access, increase therapeutic impact, and sustain long-term brand value.
A transparent, practitioner-oriented research approach combining expert interviews, technical dossier reviews, and supply-chain analysis to generate validated strategic insights
The research methodology underpinning this executive summary synthesizes primary and secondary intelligence to produce balanced, actionable insights. Primary inputs included structured interviews and targeted consultations with veterinary clinicians, regulatory experts, procurement officers, and commercial leaders to capture real-world operational perspectives and decision criteria. These engagements were complemented by product- and formulation-level technical reviews to assess development challenges and approval pathways.
Secondary inputs comprised a curated review of regulatory guidance, scientific literature, and trade publications to validate trends and contextualize policy shifts. Where relevant, supply-chain analyses were conducted to trace sourcing dependencies and logistic constraints. Throughout the process, cross-validation techniques were used to reconcile divergent viewpoints and ensure the robustness of qualitative conclusions. This combined approach emphasizes methodological transparency, triangulation of evidence, and practitioner-oriented synthesis to support credible recommendations.
A concise synthesis of strategic imperatives showing how innovation, stewardship, and supply resilience collectively shape future success in veterinary anti-infectives
In conclusion, the veterinary anti-infectives arena is at an inflection point where scientific innovation, regulatory scrutiny, and distribution transformation intersect to create both challenge and opportunity. Companies that realign R&D toward differentiated formulations, embed stewardship through diagnostic partnerships, and fortify supply chains will be best positioned to serve diverse animal health markets. Moreover, adapting commercial models to the specific demands of clinics, hospitals, retail, and online channels will accelerate adoption and improve therapeutic outcomes.
As stakeholders pursue these objectives, disciplined execution and continuous stakeholder engagement will be essential. Decision-makers should prioritize pragmatic investments that deliver measurable improvements in availability, efficacy, and compliance, while remaining vigilant to policy changes and trade dynamics that can shift operating assumptions. With a focused strategy, the industry can simultaneously advance animal health, support responsible antimicrobial use, and create sustainable commercial value.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
183 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising antimicrobial resistance driving demand for novel veterinary antibiotics and alternative therapies
- 5.2. Growth in precision livestock farming boosting targeted anti-infective delivery technologies
- 5.3. Increasing regulatory scrutiny on antibiotic use fueling adoption of bacteriophage therapies
- 5.4. Surge in companion animal healthcare spending driving innovation in species-specific anti-infectives
- 5.5. Widespread adoption of veterinary vaccines and immunomodulators reducing antibiotic reliance
- 5.6. Expansion of offshore veterinary biologics manufacturing enhancing supply chain resilience
- 5.7. Integration of point-of-care diagnostic tools with antibiotic stewardship programs in clinics
- 5.8. Development of long-acting injectable anti-infective formulations to improve treatment compliance
- 5.9. Rising investor interest in microbiome modulation therapies for livestock disease prevention
- 5.10. Implementation of digital monitoring platforms to track antibiotic usage and resistance trends on farms
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Veterinary Anti-infectives Market, by Product Type
- 8.1. Antibiotics
- 8.1.1. Aminoglycosides
- 8.1.2. Beta Lactams
- 8.1.3. Fluoroquinolones
- 8.1.4. Macrolides
- 8.1.5. Sulfonamides
- 8.1.6. Tetracyclines
- 8.2. Antifungals
- 8.2.1. Azoles
- 8.2.2. Polyenes
- 8.3. Antiparasitics
- 8.3.1. Acaricides
- 8.3.2. Anthelmintics
- 8.3.3. Insecticides
- 9. Veterinary Anti-infectives Market, by Route Of Administration
- 9.1. Injectable
- 9.1.1. Intramuscular
- 9.1.2. Intravenous
- 9.1.3. Subcutaneous
- 9.2. Oral
- 9.2.1. Pellets
- 9.2.2. Powders
- 9.2.3. Suspensions
- 9.2.4. Tablets
- 9.3. Topical
- 9.3.1. Creams
- 9.3.2. Dips
- 9.3.3. Ointments
- 9.3.4. Sprays
- 10. Veterinary Anti-infectives Market, by Animal Type
- 10.1. Aquaculture
- 10.1.1. Fish
- 10.1.2. Shrimp
- 10.2. Companion Animal
- 10.2.1. Cats
- 10.2.2. Dogs
- 10.3. Livestock
- 10.3.1. Cattle
- 10.3.2. Goats
- 10.3.3. Sheep
- 10.3.4. Swine
- 10.4. Poultry
- 10.4.1. Chicken
- 10.4.2. Turkey
- 11. Veterinary Anti-infectives Market, by Distribution Channel
- 11.1. Online Pharmacies
- 11.2. Retail Pharmacies
- 11.3. Veterinary Clinics
- 11.4. Veterinary Hospitals
- 12. Veterinary Anti-infectives Market, by Application
- 12.1. Prophylactic
- 12.2. Therapeutic
- 13. Veterinary Anti-infectives Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Veterinary Anti-infectives Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Veterinary Anti-infectives Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Ashish Life Science Private Limited
- 16.3.2. Bimeda Inc.
- 16.3.3. Biogénesis Bagó S.A.
- 16.3.4. C.H. Boehringer Sohn AG & Co. KG
- 16.3.5. Ceva Santé Animale
- 16.3.6. Dechra Pharmaceuticals PLC
- 16.3.7. Eco Animal Health Group PLC
- 16.3.8. Elanco Animal Health Incorporated
- 16.3.9. Intas Pharmaceuticals Ltd.
- 16.3.10. Krka, d. d., Novo mesto
- 16.3.11. Kyoritsuseiyaku Corporation
- 16.3.12. LABORATORIO AVI-MEX
- 16.3.13. LABORATORIOS CALIER, S.A.
- 16.3.14. Merck KGaA
- 16.3.15. Neogen Corporation
- 16.3.16. Ourofino Group
- 16.3.17. Sequent Scientific Ltd.
- 16.3.18. Vetoquinol SA
- 16.3.19. Virbac SA
- 16.3.20. Zoetis Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
